Advances in clinical neuro-oncology research on integrin PET imaging.

ABSTRACT:

Background

Angiogenesis plays a pivotal role in the progression of neuro-oncological diseases, mediated by integrin receptors on endothelial and tumor cells. Radiolabeled RGD peptides, targeting integrins such as αvβ₃, offer potential as imaging tracers for diagnosing and monitoring these diseases. This review evaluates the effectiveness and reliability of RGD-containing peptides for PET imaging in neuro-oncology, focusing on diagnostic performance, tumor delineation, and treatment response evaluation.

Methods

A systematic literature search was conducted in PubMed, EMBASE, and Cochrane Library until November 2024, identifying relevant studies using RGD-based tracers in neuro-oncological imaging. Data on patient demographics, tumor types, imaging protocols, tracer

SUBMITTER: Henssen D 

PROVIDER: S-EPMC12477096 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature